Recent National Cancer Institute Cannabis Reports Encourages Cannabis Science to Ramp Up California Product Releases, Bring More Products to Market in State by State Regulated Markets and Expedite Its Formal FDA Cancer Initiatives Much Faster

LOS ANGELES, CA--(Marketwired - Sep 28, 2015) -  Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. Company specializing in cannabis-based pharmaceutical development, is ramping up its formal and informal Cancer studies in response to the National Cancer Institute initiatives to help save millions of preventable deaths each year by raising its Cancer Studies awareness and education about cancer. The Company is focused on persuading governments and individuals across the world to expand their preventive and therapeutic actions against Cancer and other critical ailments. Cannabis Science is highly motivated to accelerate the pace of its cancer drug development studies and is ramping up its new products distribution to the California market immediately through additional product releases and additional licensing deals in each state-by-state regulated market and its formal FDA initiatives.

"Our previous success with self-medicated patient usage is a great building block for us as our increasing requests for new products from self-medicating patients and dispensaries indicate. As we already know, affected people are looking for cannabinoid treatments for all types of acute and chronic illnesses. Cancer is just one of our major targets, and building from our previous success, we are ramping up production to start fulfilling that demand. Our patient-centered outcomes program, the Patient Access Center (PAC), will use extensive feedback from patients to inform our drug development efforts. In addition, the PAC will become a critical tool in our drug development cycle," stated Mr. Raymond C. Dabney, President & CEO, Co-Founder Cannabis Science Inc., and the Cannabis Science Research Foundation.

The Company has increased its product releases through the Cannabis Science Research Foundation (CSRF) http://cannabisscienceresearchfoundation.org/

Cannabis Science has successfully released its first group of cannabinoids in California for test marketing and the positive results have been assessed as indicators to ramp up distribution and continue adding products, including pills, extracts, and creams, hiring of additional representatives and additional locations for a much larger products release. The CBIS Brand is currently being sold in multiple locations in California that are State licensed public and private cannabis dispensaries.

Cancer is one of the leading causes of death worldwide and accounts for a large proportion of disability. The number of new cancer cases will rise to 22 million within the next two decades. More than 70% of these new cases will originate in Africa, Asia, and Central and South America; and 70% of the world's cancer deaths will also occur in these regions. The predicted increases will place an unsupportable burden on the health care systems of these regions and will add to the cost burden in developed countries. The recent Global Burden of Disease Study ranks a wide variety of cancers very highly in the leading causes of disability adjusted life years. Cancers of the respiratory tract (such as lung cancer), liver, stomach, and breast cancer rank highly in developed countries and are increasing at an accelerated rate in developing countries. As the incidence of cancers worldwide is increasing both prevention and effective efficient treatment strategies will become critically important. A number of research studies point to the effectiveness of cannabinoids in the treatment of cancer. It is imperative that anti-cancer cannabinoid drug development is accelerated and that effective treatments are brought to the market efficiently and rapidly.

Please visit: http://www.cancer.gov/search/results to read these compelling research reports.

For more diverse info please visit: http://www.healthnutnews.com/

Mr. Dabney concludes, "We have and are releasing many diverse products for many different disorders that reflect the particular circumstances of each self-medicating patient. We will be releasing various products, with varying dosages and delivery methodologies, in various jurisdictions as regulatory stipulations permit. We look forward to releasing more information about additional products and locations as the information becomes available. Please feel free to contact me directly with any questions and special requests; our team is ready."

About Cannabis Science Research Foundation (CSRF)
The Cannabis Science Research Foundation, a non-profit organization, is a new source of hope for a world where countless medical conditions affect tens of millions of people in the United States and hundreds of millions Internationally. It is not just any foundation; it is an institute bringing new findings about the endocannabinoid system to light using state of the art and entrepreneurial research. The findings from the research will guide the Foundation to develop new products for the general public, enter the FDA, and perform clinical studies.

About Cannabis Science, Inc.

Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.

Forward Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.